A back-to-biology approach to cancer therapies: an interview with Berg's Dr Niven Narain

Massachusetts, USA-based biopharma company Berg is aiming to change the way we treat cancer. After the success and efficacy of very specially-targeted drugs such as Herceptin (trastuzumab), Berg is looking to develop a therapy that will treat a wide range of oncology indications, rather than focusing on a particular kind.

Back-to-biology

Berg hopes to find the answer in looking at human biology first, before formulating a therapy. Niven Narain, founder, president and chief technology officer of Berg, told The Pharma Letter: “We’re taking a back-to-biology approach to drug development. Most drugs are developed based on chemical screening and we don’t find out about the biology until they’re on the market or in late stage trials. We started the company on the premise of asking how we use biology and technology to find the pressure points in health and disease, and then start a very defined and disciplined drug development process.”